Document is current
Any future updates will be listed below
-
Authors
Chin, Kuo-Kai https://orcid.org/0000-0003-4504-398X
Abdul-Hay, Maher https://orcid.org/0000-0003-1041-7689
Shukla, Mihir
Geyer, Mark B. https://orcid.org/0000-0001-5248-9117
Tamari, Roni https://orcid.org/0000-0002-2386-0850
Ko, Kaitlyn H.
Xiao, Wenbin https://orcid.org/0000-0001-8586-8500
Stein, Eytan M.
Cai, Sheng F. https://orcid.org/0000-0002-2708-887X
- License Information
-
More Information
Article History
Received: 19 January 2026
Revised: 25 February 2026
Accepted: 27 March 2026
First Online: 10 April 2026
Competing interests
: KC participated in a steering committee for Servier Pharmaceuticals. MAH has had advisory roles with Incyte, Daiichi, Servier, Amgen, Novartis, and consulting roles with AbbVie, PureTech. MBG: Tigen Pharma, Actinium Pharmaceuticals, Amgen (research support); Takeda, Amgen (advisory). EMS served as a consultant for Daiichi Sankyo, Gilead, Genentech, Agios, Jazz, AstraZeneca, Celgene, AbbVie, Astellas Pharmaceuticals, Syndax, Kura, Johnson and Johnson, and Servier. SFC has been a consultant and/or shareholder for Daiichi-Sankyo and Ursamin, neither of which is directly related to the content of this paper. SFC has received research support from Syndax, Trio, and Actinium. SFC is an inventor on a patent related to Menin inhibition WO/2017/132398A1.
